Acquired
Veritas Genetics Stock
Genetic testing platform
Sign up today and learn more about Veritas Genetics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Veritas Genetics Stock
Veritas Genetics is a provider of a genetic testing platform intended to empower people to live healthier and longer. The company's genetic technology can detect a wider range of variations in a gene than are typically found in next-generation sequencing and offers a screening test for hereditary breast and ovarian cancer risk, enabling clinical researchers and physicians in order to make informed decisions.
Investors
Lilly Asia Ventures
Philab Holdings Corp
Simcere Pharma
Funding History
| June 2015 | $12.0M |
|---|---|
| October 2016 | $30.0M |
| January 2018 | $4.6M |
| February 2018 | $500M |
Management
Co-Founder & Chief Executive Officer
Mirza Cifric
Co-Founder & Managing Director, Asia
Jonathan Zhao
Chief Commercial Officer & General Counsel
Douglas Flood
Press
businesswire - Jul, 20 2020
Veritas Is Working to Bring Next Generation Sequencing Based COVID Testing at Scale and Improve Accessibility for Return to Work InitiativesCNBC - Dec, 5 2019
Veritas Genetics, the start-up that can sequence a human genome for less than $600, ceases US operations and is in talks with potential buyersprnewswire - Jul, 24 2019
Veritas Now Provides Whole Genome Sequencing and Interpretation for Less Than 1,000€TechCrunch - Aug, 29 2018
George Church’s genetics on the blockchain startup just raised $4.3 million from KhoslaCNBC - May, 22 2018
30. Veritas GeneticsTechCrunch - Mar, 8 2016
For less than $1,000 you can now pull up your entire genome on your smartphoneEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
